NEW YORK, NY / ACCESSWIRE / September 22, 2017 / U.S. markets retreated from record highs a day after the Federal Reserve announced that it would begin unwinding its $4.5 trillion balance sheet in October and left a possibility of an another rate hike on the table in 2017. The Dow Jones Industrial Average declined 0.24 percent to close at 22,359.23, breaking a streak of 9 consecutive daily gains, while the S&P 500 Index fell 0.30 percent to close at 2,500.60. The NASDAQ Composite Index dropped 0.52 percent to close at 6,422.69. The technology sector slumped as Apple Inc. dropped 1.7 percent due to issues with its latest smartwatch.
"The market is sorting through to what extent it needs to incorporate future Fed activity into its thinking," said Mike Allison, a portfolio manager with Eaton Vance. "There's some uncertainty as to the impact since interest rates have been so low for so long."
RDI Initiates Coverage on:
Ocera Therapeutics Inc.
Gevo Inc.'s stock jumped 33.88% on Thursday, to close the day at $0.81. The stock recorded a trading volume of 12,894,839 shares, which was above its three months average volume of 466,366 shares. In the last year, Gevo Inc.'s shares have traded in a range of 0.53 - 10.40. The share price has gained 52.83% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.60 is below its 200-day moving average of $0.79. Shares of Gevo have fallen approximately 76.59 percent year-to-date.
Access RDI's Gevo Inc. Research Report at:
On Thursday, shares in Ocera Therapeutics Inc. recorded a trading volume of 1,636,394 shares, which was above the three months average volume of 163,598 shares. The stock ended the day 24.07% higher at 1.22. The share price has gained 134.62% from its 52-week low with a 52-week trading range of 0.52 - 3.15.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.99 is below its 200-day moving average of $1.14. Shares of Ocera Therapeutics have fallen approximately 41.9 percent year-to-date.
Access RDI's Ocera Therapeutics Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.